<< Back to News

System Formulary Update
Class I Antiarrhythmics

Situation

The antiarrhythmics, class I class review and formulary standardization was approved at the July 2020 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: disopyramide, flecainide, mexiletine, procainamide, propafenone, quinidine

Assessment/Recommendation
Changes effective: Tuesday September 1, 2020

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Flecainide tablet: 50 mg, 100 mg
• Flecainide oral suspension: 20 mg/mL
• Mexiletine capsule: 150 mg, 200 mg, 250 mg
• Mexiletine oral suspension: 10 mg/mL
• Procainamide IV solution: 100 mg/mL (10 mL), 500 mg/mL (2 mL)
• Propafenone IR tablet: 150 mg, 225 mg
• Propafenone oral suspension: 20 mg/mL

Note: Stock of these products may vary at individual entities

As a result, the following products will be removed from the UNC Health Medication Formulary: 

• Quinidine oral suspension
• Disopyramide phosphate IR capsule and ER capsule
• Flecainide tablet: 150 mg tablet
• Flecainide oral suspension: 5 mg/mL
• Propafenone IR tablet: 300 mg
• Propafenone ER capsule
• Quinidine gluconate ER tablet
• Quinidine sulfate IR tablet